Quick Answer: Which Wins on Weight Loss?
In the SURMOUNT-5 head-to-head trial published in 2025, Zepbound (tirzepatide) produced an average 20.2% body-weight reduction over 72 weeks versus 13.7% for Wegovy (semaglutide). Zepbound is also the only GLP-1 FDA-approved for obstructive sleep apnea in adults with obesity. Wegovy still has broader insurance coverage and a longer real-world track record. Both are excellent; the right choice depends on your goal, history, and how your body responds.
Zepbound vs Wegovy: Side-by-Side Comparison
Trial data, FDA approvals, dosing, and 2026 pricing, all in one table.
| Category | Zepbound (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Active Ingredient | Tirzepatide (dual GIP + GLP-1) | Semaglutide (GLP-1 only) |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Average Weight Loss (clinical trials) | 20-22.5% body weight (SURMOUNT-1, 72 weeks) | 15-17% body weight (STEP-1, 68 weeks) |
| Head-to-Head Trial (SURMOUNT-5, 2025) | 20.2% average weight loss at 72 weeks | 13.7% average weight loss at 72 weeks |
| FDA Approval Year | November 2023 (weight loss); December 2024 (sleep apnea + obesity) | June 2021 (chronic weight management) |
| Maximum Dose | 15 mg weekly | 2.4 mg weekly |
| 2026 Cash Price (manufacturer direct) | LillyDirect: $349/mo (2.5 mg) - $499/mo (15 mg) | NovoCare: ~$199/mo new patients, ~$349/mo standard |
| List Price (no discount) | $1,086/month | $1,349/month |
| Insurance Coverage | Coverage expanding rapidly through 2026 | Broader commercial coverage (longer on market) |
| Sleep Apnea Indication | FDA-approved for OSA + obesity (Zepbound only) | Not FDA-approved for sleep apnea |
| Dosing Form | Pre-filled pen + single-dose vial (LillyDirect) | Pre-filled pen only |
| Most Common Side Effects | Nausea, diarrhea, constipation, decreased appetite | Nausea, vomiting, diarrhea, constipation |
FDA Approved For
Chronic weight management (Nov 2023). Obstructive sleep apnea in adults with obesity (Dec 2024).
Average Weight Loss
20-22.5% of body weight (SURMOUNT-1, 72 weeks)
2026 Cost (LillyDirect)
$349/mo (2.5 mg starter) to $499/mo (15 mg maintenance) via single-dose vials.
Maximum Dose
Best fit: patients targeting larger weight loss, those with coexisting obstructive sleep apnea, or those who plateaued on Wegovy.
FDA Approved For
Chronic weight management (June 2021). Cardiovascular risk reduction (March 2024).
Average Weight Loss
15-17% of body weight (STEP-1, 68 weeks)
2026 Cost (NovoCare)
~$199/mo for new patients, ~$349/mo standard pricing direct from Novo Nordisk.
Maximum Dose
Best fit: patients with insurance that covers Wegovy, those tolerating semaglutide well, or those with established cardiovascular risk.
The First Direct Trial: Zepbound vs Wegovy
Until 2025, every comparison between Zepbound and Wegovy was indirect, based on separate trials with different patient populations. SURMOUNT-5, published in the New England Journal of Medicine, finally put the two head-to-head in 751 adults with obesity over 72 weeks.
Zepbound (tirzepatide)
20.2%
average body-weight reduction
Wegovy (semaglutide)
13.7%
average body-weight reduction
Roughly 32% of Zepbound patients lost at least 25% of their body weight versus 16% on Wegovy. Side effects were comparable, primarily gastrointestinal and dose-related. The takeaway is not that Wegovy is "bad", 13.7% body weight loss is excellent. The takeaway is that tirzepatide's dual GIP/GLP-1 mechanism produces meaningfully more weight loss on average, which matters for patients with larger weight-loss goals or significant metabolic comorbidities.
2026 Cost: LillyDirect vs NovoCare
Both manufacturers now sell directly to patients. This has reshaped the GLP-1 market and made FDA-approved options far more affordable than the compounded alternatives that dominated 2023-2024.
LillyDirect (Zepbound)
- • 2.5 mg starter dose: $349/month
- • 5 mg dose: $499/month
- • 7.5 mg, 10 mg, 12.5 mg, 15 mg: $499/month
- • Single-dose vials shipped to your door
- • With commercial insurance + savings card: as low as $25/month
NovoCare (Wegovy)
- • New-patient introductory pricing: ~$199/month
- • Standard cash price: ~$349/month
- • Pre-filled injection pens
- • With commercial insurance + savings card: as low as $0-25/month
- • Broader commercial coverage than Zepbound (longer on market)
Prices reflect publicly available manufacturer programs as of April 2026. Actual cost varies by dose, pharmacy, and insurance. Thrive RX visits ($250 initial / $200 follow-up) are billed separately and are FSA/HSA eligible.
The Sleep Apnea Difference
In December 2024, Zepbound became the first medication ever FDA-approved for obstructive sleep apnea (OSA) in adults with obesity. In the SURMOUNT-OSA trial, Zepbound reduced apnea-hypopnea index by 25-30 events per hour alongside meaningful weight loss. Wegovy is not currently FDA-approved for sleep apnea.
If snoring, daytime fatigue, or witnessed apneas are part of your story, the workup matters. Thrive RX offers a home sleep apnea test with physician interpretation, and Dr. Kiswani-Barley can fold those results into your GLP-1 decision.
Which Should You Take?
Both Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved, highly effective weight-loss medications, and either is a reasonable starting point for most patients. In the SURMOUNT-5 head-to-head trial published in 2025, Zepbound produced significantly more weight loss than Wegovy (20.2% vs 13.7% over 72 weeks). Zepbound also has the only FDA approval for obstructive sleep apnea in adults with obesity, which can be meaningful for patients with both conditions. Wegovy has been on the market longer, has broader commercial insurance coverage, and remains a strong option, especially for patients whose insurance covers it. The right choice depends on your weight-loss goal, metabolic and sleep history, insurance, side-effect tolerance, and how your body actually responds. At Thrive RX, Dr. Kiswani-Barley personally evaluates your labs and history and prescribes the FDA-approved GLP-1 that fits you, never compounded, never one-size-fits-all.
Why Patients Choose Thrive RX for Their GLP-1
Picking the right GLP-1 is the easy part. The harder part is the medicine around it: comprehensive labs, root-cause evaluation, dose titration, side-effect management, nutrition, sleep, and a real plan for what comes next. That is where Dr. Kiswani-Barley spends her time.
Your Story Comes First
Have time to explain your symptoms, your timeline, what you have already tried, and what matters to you. Dr. Kiswani-Barley starts by listening so your concerns can guide a thoughtful assessment.
Understand Your Options
Discuss your history and concerns through secure video, then understand the assessment and next steps in plain language. When a hands-on examination or other in-person care is needed, Dr. Kiswani-Barley will recommend the appropriate setting.
Consider the Whole Picture
Explore how medical conditions, medications, sleep, nutrition, and other factors may affect how you feel. Testing and treatment are chosen for your circumstances, with attention to underlying causes when identifiable and symptom relief when appropriate.
A Real Relationship
Build a relationship with the same physician over time. Follow-up care can draw on your history, review your response to treatment, and adjust recommendations as your needs and goals change.
"I trained in Family Medicine because I wanted to know my patients, their families, their stress, the way their work and sleep and history all fit together. Modern healthcare keeps trying to strip that out. I built Thrive RX so I could put it back in."
Vandhana Kiswani-Barley, MD
Board-certified in Family Medicine, Obesity Medicine, and Pain Management, plus a Fellow of the American College of Healthcare Executives (FACHE)
Outstanding medical care and professional staff
"I highly recommend Dr. Kiswani-Barley to anyone looking for a compassionate and professional physician. The level of medical expertise and attentiveness is unmatched. Staff included provide exceptional care. They take the time to answer all questions and never make you feel rushed."
Originally posted on Google
Can't say enough good things
"I can't say enough good things about Dr. Kiswani! I am currently a hormone therapy patient of hers, but she has gone above and beyond to help me with my health. She truly cares about her patients and takes the time to listen and understand your concerns."
Originally posted on Google
Frequently Asked Questions
Weight Loss Resources
Explore related physician-led services from Thrive RX
Medical weight loss serving all of Florida
Physician-led semaglutide & tirzepatide care statewide
FDA-approved Wegovy/Ozempic for weight management
Step-by-step guide from a Florida physician
Dual GIP/GLP-1 therapy with Mounjaro/Zepbound
Transparent pricing and savings options